BMRN logo

BioMarin Pharmaceutical Inc. (BMRN)

$58.51

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on BMRN

Market cap

$11.33B

EPS

-0.08

P/E ratio

--

Price to sales

3.11

Dividend yield

--

Beta

0.211732

Price on BMRN

Previous close

$57.99

Today's open

$57.95

Day's range

$57.33 - $58.65

52 week range

$49.26 - $70.98

Profile about BMRN

CEO

Alexander Hardy

Employees

3221

Headquarters

San Rafael, CA

Exchange

Nasdaq Global Select

Shares outstanding

193694734

Issue type

Common Stock

BMRN industries and sectors

Healthcare

Biotechnology & Life Sciences

News on BMRN

BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies Global Healthcare Conference 2026 Transcript

BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • Nov 17, 2026

news preview

BioMarin Pharmaceutical Sees $2.6 Billion Sales Potential in Amicus Drugs as VOXZOGO Expansion Looms

BioMarin Pharmaceutical NASDAQ: BMRN expects growth from its acquired rare disease treatments, an expanded market for VOXZOGO and a pipeline that could deliver patient data in 2027, Chief Executive Officer Alexander Hardy said at the UBS Global Biopharma Conference.

news source

MarketBeat • Nov 16, 2026

news preview

BioMarin Pharmaceutical Inc. (BMRN) Presents at UBS Global Biopharma Conference 2026 Transcript

BioMarin Pharmaceutical Inc. (BMRN) Presents at UBS Global Biopharma Conference 2026 Transcript

news source

Seeking Alpha • Nov 16, 2026

news preview

BioMarin Pharmaceutical Hits $1 Billion Revenue Milestone, Advances Rare-Disease Pipeline

BioMarin Pharmaceutical NASDAQ: BMRN is advancing a group of newly acquired rare-disease drug candidates while integrating Amicus Therapeutics and working to reduce debt, executives said during a company discussion.

news source

MarketBeat • Nov 12, 2026

news preview

BioMarin Pharmaceutical Inc. (BMRN) Presents at Stifel 2026 Healthcare Conference 2026 Transcript

BioMarin Pharmaceutical Inc. (BMRN) Presents at Stifel 2026 Healthcare Conference 2026 Transcript

news source

Seeking Alpha • Nov 12, 2026

news preview

BioMarin to Participate in Upcoming Investor Conferences

Stifel Healthcare Conference, November 11 at 3:20 pm EST UBS Global Biopharma Conference, November 16 at 9:20 am GMT Jefferies Global Healthcare Conference, November 17 at 11:30 am GMT SAN RAFAEL, Calif., Nov. 4, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in November.

news source

PRNewsWire • Nov 4, 2026

news preview

BioMarin: Better Risk-Reward Ahead Of Three FDA Decisions

BioMarin's lower valuation and broader commercial portfolio now offer a better entry point compared with my previous Hold rating on this name. Voxzogo's potential hypochondroplasia expansion is a nice growth catalyst, and a full approval would further strengthen BMRN's existing achondroplasia franchise. Their Amicus acquisition also brings new revenue sources, though I reckon it remains to be seen if it fully justifies the debt required to finance the transaction.

news source

Seeking Alpha • Nov 4, 2026

news preview

BioMarin Pharmaceutical Inc. (BMRN) Q3 2026 Earnings Call Transcript

BioMarin Pharmaceutical Inc. ( BMRN ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants Traci McCarty - Group Vice President Alexander Hardy - President, CEO & Director Cristin Hubbard - Executive VP & Chief Commercial Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Brian Mueller - CFO & Executive VP of Finance Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Eliana Merle - Barclays Bank PLC, Research Division Adithya Jayaraman - Evercore Inc. Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Alexandria Hammond - Wolfe Research, LLC Rakesh Kumar Joon Lee Olivia Brayer - Cantor Fitzgerald & Co., Research Division Christopher Raymond - Raymond James & Associates, Inc., Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Presentation Operator Hello, everyone. Thank you for joining us, and welcome to the BioMarin Third Quarter 2026 Conference Call.

news source

Seeking Alpha • Nov 3, 2026

news preview

BioMarin Pharmaceutical Q3 Earnings Call Highlights

BioMarin Pharmaceutical NASDAQ: BMRN reported third-quarter revenue above $1 billion for the first time, driven by growth across its rare-disease portfolio and contributions from acquired Amicus Therapeutics products. The company said revenue increased 32% year over year, while its metabolic conditions business grew 44%.

news source

MarketBeat • Nov 3, 2026

news preview

BioMarin Reports Third Quarter 2026 Financial and Operating Results

Third Quarter 2026 Total Revenues Increased 32% Y/Y to $1.025 billion; Growth Driven by 44% Increase in Metabolic Conditions Y/Y, and 12% Increase in Skeletal Conditions Y/Y Updates Full-year 2026 Guidance to Reflect Order Timing Uncertainty and Impact of Two Acquired In-process Research and Development (IPR&D) Charges Recently Announced the Addition of a New Investigational Fabry Asset to Clinical Portfolio PDUFA Action Date of May 30, 2027 for VOXZOGO® for the Treatment of Hypochondroplasia (HCH) Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif.

news source

PRNewsWire • Nov 2, 2026

news preview

¹ Disclosures

Get started with M1

Invest in BioMarin Pharmaceutical Inc.

Open an M1 investment account to buy and sell BioMarin Pharmaceutical Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in BMRN on M1